Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ALIMTA plus doxorubicin in advanced breast cancer
2004-000691-13Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2004
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed and doxorubicin in breast cancer, sponsored by Eli Lilly and Company. Primary endpoint: Overall tumor response rate. Started Nov 2004; status: completed.
02
Drugs
pemetrexeddoxorubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2004-000691-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000691-13.